HC Wainwright Reaffirms Buy Rating for Biomea Fusion (NASDAQ:BMEA)

Biomea Fusion (NASDAQ:BMEA)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $40.00 target price on the stock.

Several other brokerages also recently commented on BMEA. Truist Financial upgraded Biomea Fusion from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a report on Friday, September 27th. EF Hutton Acquisition Co. I raised Biomea Fusion to a “strong-buy” rating in a research report on Wednesday, October 9th. RODMAN&RENSHAW upgraded Biomea Fusion to a “strong-buy” rating in a report on Thursday, September 26th. Barclays boosted their target price on Biomea Fusion from $9.00 to $11.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. Finally, Rodman & Renshaw raised shares of Biomea Fusion from a “neutral” rating to a “buy” rating and set a $18.00 price target for the company in a research note on Thursday, September 26th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $30.50.

Biomea Fusion Price Performance

Shares of Biomea Fusion stock opened at $6.44 on Thursday. The firm has a market cap of $233.39 million, a P/E ratio of -1.61 and a beta of -0.41. Biomea Fusion has a fifty-two week low of $3.61 and a fifty-two week high of $22.74. The firm has a 50 day simple moving average of $9.40 and a 200 day simple moving average of $7.94.

Biomea Fusion (NASDAQ:BMEA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.03. On average, sell-side analysts expect that Biomea Fusion will post -3.93 EPS for the current year.

Insider Buying and Selling

In other Biomea Fusion news, Director Michael J.M. Hitchcock acquired 10,000 shares of the company’s stock in a transaction on Monday, September 30th. The shares were purchased at an average price of $10.06 per share, for a total transaction of $100,600.00. Following the completion of the purchase, the director now directly owns 15,000 shares of the company’s stock, valued at approximately $150,900. This represents a 200.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 27.57% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Biomea Fusion

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Biomea Fusion during the 2nd quarter worth about $36,000. High Net Worth Advisory Group LLC acquired a new stake in Biomea Fusion during the second quarter worth approximately $45,000. Scientech Research LLC bought a new stake in shares of Biomea Fusion during the second quarter worth approximately $46,000. DRW Securities LLC acquired a new position in shares of Biomea Fusion in the second quarter valued at approximately $55,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Biomea Fusion by 64.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 6,964 shares of the company’s stock worth $70,000 after purchasing an additional 2,741 shares during the period. 96.72% of the stock is owned by institutional investors.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.